Create accountLogin

Recent searches

No recent searches

Search options

Only available when logged in.
med-mastodon.com is one of the many independent Mastodon servers you can use to participate in the fediverse.
Medical community on Mastodon

Administered by:

Server stats:

411
active users

med-mastodon.com: AboutProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.8

#TumorBoardTuesday

0 posts0 participants0 posts today
Public
TumorBoardTuesday

A very complex, but thought-provoking & necessary #TumorBoardTuesday
What happens when you have a patient on biologic therapy for an autoimmune disease/#IBD & they need #BreastCancer treatment?

Weigh in!

36yo 👩🏻‍🦱 self palpates a R breast mass.
PMH: Crohn’s disease - dx 34yo, perianal fistula w/abscess, achieving remission with infliximab/AZA.
🧪Workup: T2N1 TNBC germline neg

🤨What option would you consider?

@MPishvaian @JohnEbbenMDPhD
@breastcancernow @breastcancer @tumorboard

· 1 person · Closed
Public
TumorBoardTuesday

Thank you to @jessrzanotti & @RachelRiechelm2 for an exceptional #TumorBoardTuesday on hypermutation in #NET- how might this change care in the future?

Check out thread below & answer the question at the end to get free #CME!

Special edition of Case Wrap Up drops tomorrow!💡
---
RT @jessrzanotti
@TumorBoardTues @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD @PamelaKunzMD @marklewismd @DianeReidyLagun @timpawlik @CanHealeu @duiliorocha_…
twitter.com/jessrzanotti/statu

TwitterJéssica Zanotti on Twitter“@TumorBoardTues @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD @PamelaKunzMD @marklewismd @DianeReidyLagun @timpawlik @CanHealeu @duiliorocha_onc @RenataDAlpino @DBulzico @Juanmaoconnor @Nanodioca @OncoThor @helops79 @rcarvalhoonco @donadio_ds @leogilsan @ManikAmin4 @chirayumohin @carlacav @realbowtiedoc @jaypsv @viniciu_antonio @letswinpc 6/15 #TumorBoardTuesday 👩🏻‍🏫Mini tweetorial 2👩🏻‍🏫 📌MSI biomarker 📍≤ 10% of neuroendocrine carcinoma 📍MSI & TMB-h rare in G3 (<1%) 📍Hypermutation may be induced by temozolamide in #gliomas and #NETCancer 📍Molecular profiling upon DP on alkylating agents may find TMB-h”
Public
Johnathan Ebben MD, PhD

🤯 NETs usually NOT responsive to IO...but there may be a way to direct tumor evolution to CAUSE hypermut (TMZ/alkylator exposure- ~10% of cases), select for dMMR subclones, drive ⬆️TMB 👉 ⬆️ IO resp in next line. Fascinating ! @jessrzanotti & @RachelRiechelm2
---
RT @jessrzanotti
@TumorBoardTues @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD @PamelaKunzMD @marklewismd @DianeReidyLagun @timpawlik @CanHealeu @duiliorocha_…
twitter.com/jessrzanotti/statu

TwitterJéssica Zanotti on Twitter“@TumorBoardTues @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD @PamelaKunzMD @marklewismd @DianeReidyLagun @timpawlik @CanHealeu @duiliorocha_onc @RenataDAlpino @DBulzico @Juanmaoconnor @Nanodioca @OncoThor @helops79 @rcarvalhoonco @donadio_ds @leogilsan @ManikAmin4 @chirayumohin @carlacav @realbowtiedoc @jaypsv @viniciu_antonio @letswinpc @pedrojfreire @MadisonConces @AGangiMD @gi_campiolo @ClaudioVladmir @PoHienEar @ArndtVogel @drallysonocean @aparna1024 @anup_kasi @HannahAlison20 @SebLange @Mvgs1706 @rachaelguenter @Ja_Capdevila @AmanChauhanMD @PatrickMcGarrah @sonbol_bassam @NirajGusani @cives_mauro @altoubaht 10/15 #TumorBoardTuesday 👩🏻‍🏫Mini tweetorial 6👩🏻‍🏫 There’s limited evidence for immunotherapy in molecularly unselected #NETCancer Hypermutated G3 #NETCancer cases have a response to immunotherapy 📚https://t.co/rP0KRjSqr9 📚https://t.co/KRfLoLL0TP”
Public
Johnathan Ebben MD, PhD

It's here! featuring latest management strategies for NET, including hypermutated NET. Can't wait to learn 📚!
---
RT @jessrzanotti
@TumorBoardTues 1/15
46yo 👩🏻 asymptomatic
no comorb
🌀Screening abd US: liver nodules + pancreatic mass (body/tail)
🔬Liver bx + NET G2 Ki67 12%
🩻PET-Ga + uptake in pancreas & liver (SUVs>20)
💉1L: Lanreotide SC - DP liver after 1y (⬆️volume)
🤨What 2L …
twitter.com/jessrzanotti/statu

TwitterJéssica Zanotti on Twitter“@TumorBoardTues 1/15 #TumorBoardTuesday #PanCan #OncTwitter 46yo 👩🏻 asymptomatic no comorb 🌀Screening abd US: liver nodules + pancreatic mass (body/tail) 🔬Liver bx + NET G2 Ki67 12% 🩻PET-Ga + uptake in pancreas & liver (SUVs>20) 💉1L: Lanreotide SC - DP liver after 1y (⬆️volume) 🤨What 2L tx?”
Public
TumorBoardTuesday

📢 Join our 🇧🇷 Brazilian-led #TumorBoardTuesday!!

🥼@RachelRiechelm2 @jessrzanotti teach us treating hypermutation induced in NET #PancreaticCancer
👇🏽

📱Weigh in
🧾Bring receipts
🙋Ask Q’s
📊check polls
🔁RT
👩🏻‍⚕️tag peers
@MPishvaian @JohnEbbenMDPhD
#MedTwitter #WomenInOncology
---
RT @jessrzanotti
@TumorBoardTues 1/15 #TumorBoardTuesday #PanCan #OncTwitter
46yo 👩🏻 asymptomatic
no comorb
🌀Screening abd US: liver nodules + pancreatic mass …
twitter.com/jessrzanotti/statu

TwitterJéssica Zanotti on Twitter“@TumorBoardTues 1/15 #TumorBoardTuesday #PanCan #OncTwitter 46yo 👩🏻 asymptomatic no comorb 🌀Screening abd US: liver nodules + pancreatic mass (body/tail) 🔬Liver bx + NET G2 Ki67 12% 🩻PET-Ga + uptake in pancreas & liver (SUVs>20) 💉1L: Lanreotide SC - DP liver after 1y (⬆️volume) 🤨What 2L tx?”
Public
TumorBoardTuesday

🦓1 hour until TONIGHT'S #TumorBoardTuesday!!

🇧🇷@RachelRiechelm2 @jessrzanotti take us through treatment of hypermutation induced by alkylating agent in #PanCan

🦓Finish dinner, grab a drink, and prepare your 🧠 with these #CME

👇🏽See you soon!

---
RT @TumorBoardTues
#TumorBoardTuesday #PreTest Q1⃣
Free #CME🔗integrityce.com/TBT2023

📣B4 @RachelRiechelm2 @jessrzanotti teach us hypermutation #NETCancer test your🧠

🤔Which 2L fo…
twitter.com/TumorBoardTues/sta

GIF
Continued thread
Public
TumorBoardTuesday

Remember #TumorBoardTuesday continues to offer CME credit for FREE! Don’t forget to answer the polls👇🏽
Then click this link to quickly request your credit!
CME eval🔗: integrityce.com/TBTeval23
ALL CME 🔗: integrityce.com/TBT2023

---
RT @JennyCarlisleMD
@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20…
twitter.com/JennyCarlisleMD/st

www.surveymonkey.comTumor Board Tuesday Evaluation 2023 (ID: i854/i855/i862/i865)Take this survey powered by surveymonkey.com. Create your own surveys for free.
Continued thread
Public
TumorBoardTuesday

7/8 #TumorBoardTuesday
Thurs Case🎀

On the horizon: 1L ex20 directed tx
🦋PAPILLON= ami: clinicaltrials.gov/ct2/show/NC
‼️ EXCLAIM-2=mobo:
clinicaltrials.gov/ct2/show/NC

Both use plat backbone. NEED better solutions to plat chemo shortage that could limit ability to provide the best care!

clinicaltrials.govA Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions - Full Text View - ClinicalTrials.govA Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions - Full Text View.
Public
Johnathan Ebben MD, PhD

Huge thanks to @JennyCarlisleMD & @LealTiciana for taking us through the use of 2 new agents in EGFR ex20ins . @LealTiciana makes a great point- being able to provide best care starts w having the most complete info, which means choosing the right NGS strat. 🩸🎯🧬
---
RT @TumorBoardTues
3/8
Thurs Case🎀
🎥 TBT in a video: Pt 1-
@LealTiciana takes us through importance of NGS–but not just any NGS.

🔹RNA/DNA based…
twitter.com/TumorBoardTues/sta

Public
TumorBoardTuesday

Remember #TumorBoardTuesday continues to offer CME credit for FREE! Don’t forget to answer the polls👇🏽
Then click this link to quickly request your credit!
CME eval🔗: integrityce.com/TBTeval23
ALL CME 🔗: integrityce.com/TBT2023

---
RT @JennyCarlisleMD
@TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @Exon20…
twitter.com/JennyCarlisleMD/st

www.surveymonkey.comTumor Board Tuesday Evaluation 2023 (ID: i854/i855/i862/i865)Take this survey powered by surveymonkey.com. Create your own surveys for free.
ExploreLive feeds
About